MedTrace Logo

Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

NCT00546143 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-09-02

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma

Conditions

Interventions

DRUG

Omalizumab

DRUG

Omalizumab

DRUG

Omalizumab

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis investigative site

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-08-31

Countries

  • Germany
  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546143 on ClinicalTrials.gov